GeneAssess, Inc., a New Jersey-based biotechnology company, has received a commitment of up to $500k from Foundation Venture Capital Group (FVCG).
The company intends to use the funding to validate FRY, a cancer molecular signature gene discovered its scientists that could provide a more accurate diagnostic biomarker for cancer staging.
GeneAssess was founded by Dr. Helmut Zarbl, a professor of environmental and occupational medicine at Robert Wood Johnson Medical School, a member of the Environmental & Occupational Health Sciences Institute (EOHSI), and the Associate Director for Public Health Science at The Cancer Institute of New Jersey.
FinSMEs
02/07/2012